Predictive Oncology Inc. (POAI) uses artificial intelligence technology to develop customized cancer treatments for the patients. The company utilizes a database to regulate different therapies to remove the tumor. The AI based method is more effective for oncological research. The company also makes products for collection and disposal of body fluids which are infectious in nature.
The price of POAI stock at last check, in the regular trading session of December 16, 2021 was $0.95 with a slight decline of 2.43%.
Events and Happenings
On December 07, 2021, POAI announced Pamela Bush joined the company’s top management as senior vice president of Strategic Sales and Business Development. Bush had two decades of experience in business development under her belt and would unleash her potential in marketing of company’s oncology-based technologies.
On December 01, 2021, POAI announced the purchase of zPREDICTA. zPREDICTA is pioneering in the field of in vitro tumor-specific 3D cell culture for discovery and development of drug. With immediate effect, the new purchase acts as a revenue generator for the company and thus contributes to the development of new oncology-based therapeutics. On the basis of zPREDICTA’s historic and remarkable results in drug discovery and development, the company believe that the purchase will prove beneficial for the company in the future.
On November 10, 2021, POAI reported the financial highlights for the third quarter ended September 30, 2021, which, according to company management showed strong potential for future progress. Some of the important features are
For the third quarter of 2021, the Company reported revenue of $0.31 milion as opposed to $0.48 million for the same quarter of prior year.
Total Current Assets
The total current assets of the company reported were $43 million for Q3 2021 s compared to the same quarter of 2020 when they were $3.4 million.
Net loss per Share
Basic and diluted net loss per share was reported to be $5.4 million or $0.08 per share for Q3 2021 as oppsosed to basic and diluted net loss of $6.8 million or $0.46 per share. The net loss reduced over the year.
On October 19, 2021, POAI launched a website that highlighted its role in progressing AI powered treatments. The website contains information regarding POAI and subsidiaries and their main goal of elimination of cancer.
The stock price of the company showed a significant fall of 13% from the past month mostly due to uncertain factors. Still the investors are quite optimistic about the company’s stock as predicted by the company’s balance sheet.